HCPCS Level II code J1302 denotes the injection product sutimlimab-jome, reported in 10 mg units, and applies to outpatient pharmacologic infusion or injection services. This biologic therapy is relevant nationally for providers, payers, and billing teams because accurate coding affects medical record clarity, payer adjudication, and patient access to specialty therapies. Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find an overview of the code's clinical context and typical service setting, plus operational benchmarks and policy considerations affecting coverage and billing workflows. The publication summarizes payer coverage patterns, common billing practices, and relevant claim edit considerations for reporting biologic injections in outpatient settings. Where input data is incomplete, the report identifies gaps and lists items marked as "Data not available in the input." The goal is to provide concise, nationally focused information to inform revenue cycle, clinical administration, and payer contracting discussions around reporting and processing of J1302.